The medical technology company iCAD is set to present new real-world evidence (RWE) at the European Congress of Radiology (ECR) 2023 supporting its ProfoundAI software in assisting radiologists with breast cancer detection and assessment. The company will also display its Breast AI platform at its vendor booth during the meeting.
According to iCAD, “In a research presentation session on Friday, March 3 from 16:00-17:30 CET, Kathy Schilling, MD, Medical Director, Christine E. Lynn Women’s Health & Wellness Institute, Boca Raton Regional Hospital, USA, will present findings from a study titled “Real-world breast cancer screening performance with digital breast tomosynthesis before and after implementation of an artificial intelligence detection system.” After comparing the performance of nine dedicated breast radiologists reading screening digital breast tomosynthesis (DBT) exams two years before and two years after adopting ProFound AI for DBT, researchers found ProFound AI helped radiologists find 1.31 more cancers per 1,000 screening exams for a 23% relative increase in cancer detection rate, without increasing the rate of recalls.”
To read more, click here.
(Source: iCAD, March 1st, 2023)